News & Events

Nanopharm & Fluidda publish on in vitro-in silico approaches for demonstrating bioequivalence for OINDP in IPT 2022

Click here to read our joint article discussing the in vitro-in silico ‘alternative’ bioequivalence pathway for generic inhaled drug products, and how to factor in patient variability to successfully replace your comparative clinical end-point study by using SmartTrack, an in vitro in silico platform developed jointly by Nanopharm and Fluidda

Innovations in Pharmaceutical Technology, December 2022, pages 38-42. © Samedan Ltd